AstraZeneca plc (AZN)
| Market Cap | 181.45B |
| Revenue (ttm) | 29.53B |
| Net Income (ttm) | 3.77B |
| Shares Out | 3.10B |
| EPS (ttm) | 1.44 |
| PE Ratio | 40.75 |
| Forward PE | 16.50 |
| Dividend | $1.39 (2.38%) |
| Ex-Dividend Date | Aug 12, 2021 |
| Volume | 16,596,512 |
| Open | 56.16 |
| Previous Close | 55.56 |
| Day's Range | 56.08 - 58.60 |
| 52-Week Range | 46.11 - 60.45 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 62.99 (+7.7%) |
| Est. Earnings Date | Nov 12, 2021 |
About AZN
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbico...
Financial Performance
In 2020, AstraZeneca's revenue was $26.62 billion, an increase of 9.16% compared to the previous year's $24.38 billion. Earnings were $3.14 billion, an increase of 156.23%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AstraZeneca stock is "Buy." The 12-month stock price forecast is 62.99, which is an increase of 7.67% from the latest price.
News
AstraZeneca To Inject $360M In Irish API Manufacturing Site
AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The planned investment at the Alexion Campus in...
Here's Why Everyone's Talking About AstraZeneca Right Now
The company's next-generation treatment for breast cancer could become the new standard of care.
AstraZeneca to invest $360 million in Irish drug manufacturing site
(Reuters) -AstraZeneca said on Tuesday it would invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs), or the main components of medicines.
Breakthrough AstraZeneca Breast Cancer Drug Massively Reduces Disease and Fatalities in Trial
If all AstraZeneca did in the last year was team with Oxford University in a heroic quest to design, test, and deliver in record time one of the.
Why AstraZeneca and Surface Oncology Rose Today
The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi.
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor tests. What Happened: The Phase 3 DESTINY-...
Why AstraZeneca Shares Are Trading Higher Today
AstraZeneca PLC (NASDAQ: AZN) is trading higher Monday after the company announced its Enhertu data that was presented at the European Society for Medical Oncology showed reduced risk of disease progres...
AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data
AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus either carboplatin or cisplatin. The I...
AstraZeneca's EVP on the potential of the pharma giant's new breast cancer drug
AstraZeneca Executive Vice-President of the Oncology Business Unit David Frederickson discusses the drugmaker's Enhertu breast cancer drug trial results.
AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki). The trial include...
2 Pharma Stocks You Can Buy and Hold for the Next Decade
Both stocks have grabbed plenty of headlines over the past year.
Got $3,000? Keep It Safe With These 3 Healthcare Stocks
They offer products that their customers absolutely can't do without, and they also pay dividends.
3 No-Brainer Stocks to Invest $100 in Right Now
You don't need a giant pile of cash to generate a healthy return from this trio of growth, value, and income stocks.
AstraZeneca (AZN) Asthma Candidate Meets Primary Study Goals
AstraZeneca's (AZN) phase III studies evaluating its investigational inhaler PT027 for asthma meets primary endpoints.
Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?
Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.
AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings
POSEIDON Phase 3 trial results showed AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy, extended survival in lung cancer patients. The combo therapy topped overall su...
AstraZeneca's Two Asthma Trials Meet Primary Endpoints
Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of albuterol and budesonide developed ...
European Medicines Agency Lists Nerve Disorder As “Very Rare” Side Effect Of AstraZeneca Covid-19 Vaccine
The incidence of the side effect remains extremely rare with only 833 cases being reported worldwide from about 592 million administered doses of the AstraZeneca vaccine.
EMA To Add New Side Effects To Janssen, AstraZeneca COVID-19 Shots
The European Medicines Agency (EMA) has finalized to update the product information of COVID-19 vaccines developed by Johnson & Johnson (NYSE: JNJ) and AstraZeneca plc (NASDAQ: AZN) to reflect several n...
4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam
Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage.
AstraZeneca's (AZN) Ultomiris Gets EU Nod for Rare Disease in Kids
AstraZeneca's (AZN) Ultomiris receives expanded approval in the EU to treat children and adolescents with PNH, a rare disease.
Thermo Fisher (TMO)-AstraZeneca to Co-Develop NGS-Based CDx
Thermo Fisher's (TMO) new collaboration with AstraZeneca is intended to speed up development and introduction of targeted precision medicine therapies for patients.
AstraZeneca Enters Another Major Market With This Indication
The pharma giant recently received approval to market Forxiga as a treatment for chronic kidney disease patients in Japan.
AstraZeneca's Ultomiris Scores European Nod For Rare Blood Disorder In Kids, Adolescents
The European Commission has approved Alexion's Ultomiris (ravulizumab) paroxysmal nocturnal hemoglobinuria (PNH) in children (with a bodyweight of 10 kg or above) and adolescents. Alexion became a part ...